Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718708 | 0.86 | CCR9 (0.37) | TRPV4DAOGRIN2BTKTKDM1A | |
| SCHEMBL12464342 | 0.79 | DAO (0.40) | TRPV4DAOTKTKDM1AMAOA | |
| SCHEMBL17583187 | 0.77 | GRIN2B (0.38) | TRPV4DAOGRIN2BTKTKDM1A | |
| SCHEMBL29649716 | 0.72 | TRPV4 (0.40) | TRPV4KCNH2 | |
| SCHEMBL21300025 | 0.72 | CCR1 (0.46) | TRPV4 | |
| SCHEMBL17586504 | 0.72 | TRPV4 (0.40) | TRPV4KCNH2 | |
| SCHEMBL12266677 | 0.72 | KDM4E (0.41) | TRPV4DAOGRIN2BTKTKDM1A | |
| SCHEMBL17583121 | 0.71 | KCNQ3 (0.42) | PPARD | |
| SCHEMBL26151644 | 0.71 | TRPV4 (0.39) | TRPV4 | |
| SCHEMBL18397012 | 0.71 | TRPV4 (0.39) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2025-10-14 | — | — | US | disclosed |
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | IDH2, IDH3A, IDH1 | TRPV4 4417/4885DAO 2366/4885GRIN2B 1603/4885 |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | IDH2, IDH3A, IDH1 | TRPV4 4417/4885DAO 2366/4885GRIN2B 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.